PWM
HUMA icon

Perigon Wealth Management’s Humacyte HUMA Stock Holding History

Perigon Wealth Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.14K Buy
+11,707
New +$10.8K ﹤0.01% 1433

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
LWM
LJI Wealth Management Indianapolis, Indiana $714M AUM 21.51% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return
EWM
Endowment Wealth Management Appleton, Wisconsin $259M AUM 15.06% 1-Year Est. Return

Perigon Wealth Management's HUMA Position: Q2 2026 in Review

Perigon Wealth Management opened a new position in Humacyte (HUMA) in Q2 2026: 11,707 shares worth $9.14K. The stake represents ﹤0.01% of the portfolio and ranks #1433 among its holdings.

66 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Perigon Wealth Management held 11,707 shares of Humacyte worth $9.14K as of Q2 2026.
  • Humacyte was a new Perigon Wealth Management position in Q2 2026.
  • Humacyte made up ﹤0.01% of Perigon Wealth Management's portfolio in Q2 2026, its #1433 holding.
  • 66 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Perigon Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.